Carl Zeiss Meditec AG (XSWX:AFX) Growth Rank: 6 (As of Jul. 15, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
70 GF Score
Price CHF26.30
GF Value CHF61.00
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Growth Rank?

Carl Zeiss Meditec AG XSWX:AFX 70 Growth Rank is 6 as of Jul. 15, 2026, which is 33% below its 10-year median of 9.00. GuruFocus rates XSWX:AFX with a GF Score™ of 70/100 and a GF Value™ of CHF61.00 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Carl Zeiss Meditec AG has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Carl Zeiss Meditec AG Growth Rank Related Terms

XSWX:AFX vs ISRG, BDX, MDLN: Growth Rank Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Growth Rank distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Growth Rank falls into.


XSWX:AFX
70GF Score
Carl Zeiss Meditec AG XSWX:AFX
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 6 mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Growth Rank of 6 as of Jul. 15, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Carl Zeiss Meditec AG and its competitors. This is 33% below median its historical median of 9.00. Over the past decade, Carl Zeiss Meditec AG's Growth Rank has ranged from 3.00 to 10.00.
Is Carl Zeiss Meditec AG's Growth Rank too high?
Carl Zeiss Meditec AG's current Growth Rank of 6 is 33% below median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Growth Rank compare to ISRG and BDX?
Carl Zeiss Meditec AG's Growth Rank of 6 can be compared against companies in the Medical Devices & Instruments industry. Historically, Carl Zeiss Meditec AG's own Growth Rank has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Growth Rank is 6, which is 33% below median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF61.00, compared to a current price of CHF26.30 — trading 56.9% below its estimated fair value. The current Growth Rank is 6, which is 33% below median its 10-year median of 9.00. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Growth Rank is 6 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF26.30 is trading 56.9% below its estimated GF Value™ of CHF61.00. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • Growth Rank: 6 (33% below median its 10-year median of 9.00)
  • GF Value™: CHF61.00 vs. price of CHF26.30 (56.9% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score

Get the complete analysis for XSWX:AFX

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.30
Price
CHF61.00
GF Value